Ariad storms back with an FDA nod to get Iclusig back on the U.S. market

Damian Garde

Losing more than $ 2.5 billion in value didn't kill Pharmaceuticals, and now the biotech is set to relaunch the once-spurned cancer drug in the as the FDA has approved a new label and indication for the company's only product.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS